Kornimate/medical-research-clean huggingface dataset:
physical therapy in addition to standard care following c-section

Conditions: Low Back Pain; Pelvic Pain; Scar Tissue; Adhesions

Summary: the purpose of this study is to determine whether a physical therapy program which includes scar management, core retraining, and lumbar and pelvic joint mobilization will significantly impact the postpartum recovery following cesarean section during the immediate postpartum period and during the first 1.5 years following childbirth. all patients who enroll in the study will receive standard treatment following a c-section delivery. subjects will be randomized into one of two groups; one group will receive physical therapy in addition to standard post c-section treatment, and the other group will receive standard post c-section treatment with no additional physical therapy. both groups will complete questionnaires regarding their pain and recovery from c-section delivery to determine if there is a difference in recovery between the group receiving physical therapy and the group not receiving physical therapy.

cesarean section (c-section) represents the most commonly performed inpatient surgical procedure, with recent prevalence estimates of 1.3 million annually (approximately 22% of first births) in the united states. currently, postoperative recovery support is typically characterized by verbal and written instructions regarding lifting and pelvic rest as well as slow return to activity and exercise. there are multiple known complications during and after the postpartum period following cesarean section deliveries. some of the most common are back pain (up to 53% prevalence reported), bowel and bladder issues (20-30% prevalence reported), and scar tissue/adhesions. multiple studies have indicated a higher incidence of low back and pelvic girdle pain in patients following cesarean section compared to an unassisted vaginal delivery (estimates range from 2-5 times increase). the purpose of this study is to determine whether a physical therapy program which includes scar management, core retraining, and lumbar and pelvic joint mobilization will significantly impact the postpartum recovery following cesarean section during the immediate postpartum period and during the first 1.5 years following childbirth.

Eligibility criteria:
inclusion criteria: * caesarean section delivery, english speaking exclusion criteria: * heart problems, postpartum eclampsia, any medical issue which contraindicates exercise, active untreated infection, chronic narcotic use

Keywords: cesarean section postpartum issues
restoring anatomy of ruptured achilles tendon

Conditions: Achilles Tendon Rupture

Summary: the goal of this clinical trial is to investigate a new surgical approach to restore the anatomy of a ruptured achilles tendon. we will use a new two-layer technique followed by rehabilitation and find out how it influence the patients clinical outcome, muscle and tendon structure, and function after one year and compare with a standard non-surgical approach followed by rehabilitation. participants will be randomized to 1) newsur: a new two-layer surgical technique followed by rehabilitation regime or 2) conser: a standard non-surgical treatment followed by rehabilitation . we hypothesize that restoring the anatomy of the ruptured mid-substance achilles tendon using a new two-layer surgery technique followed by rehabilitation will yield a more favorable patient reported outcome (atrs) one year after rupture compared to standard non-surgical treatment followed by rehabilitation.


Eligibility criteria:
inclusion criteria: * diagnosed with a complete mid-substance achilles tendon rupture based on clinical exam, including thompson/matles test, by an experienced physician. * presented within 14 days from injury. * understands and reads danish. * no contraindications for mri. exclusion criteria: * smoking * diabetes * other injuries affecting their lower limb function. * contralateral achilles tendon rupture. * re-rupture. * anticoagulation treatment. * inability to follow rehabilitation or complete follow-up tests. * immunosuppressive treatment, including systemic corticosteroid treatment. * pregnant

Keywords: achilles tendon rupture mri surgery restore anatomy heel-rise test rehabilitation
ledipasvir/sofosbuvir in adults with chronic hepatitis c virus (hcv) infection who are on dialysis for end stage renal disease

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of this study are to evaluate the safety, efficacy and tolerability of treatment with ledipasvir/sofosbuvir (ldv/sof) in adults with chronic hcv infection who are on dialysis for esrd.


Eligibility criteria:
key inclusion criteria: * chronic hcv infected genotype 1, 2 (taiwan only), 4, 5, or 6 male and nonpregnant/ nonlactating females aged 18 years or older who are on dialysis for esrd, including adults with hiv coinfection if they are suppressed on a stable, protocol-approved antiretroviral (arv) regimens for ≥8 weeks prior to screening. note: other protocol defined inclusion/ exclusion criteria may apply.
microbiome-directed food for sustained recovery from acute malnutrition

Conditions: Acute Malnutrition With no Complications

Summary: the goal of this experimental study is to test the efficacy of a new formulation - the microbiome-directed food (mdf) to treat acute malnutrition among children aged 6 to 23 months. the main questions are: * does treating children with moderate or severe uncomplicated malnutrition using mdf leads to higher programmatic recovery rate compared to standard of care ? * does treating children with moderate or severe uncomplicated malnutrition using mdf leads to higher sustained recovery rate compared to standard of care ? the mdf will be compared to ready-to-use supplementary food (rusf) for moderately malnourished children, and to ready-to-use therapeutic food (rutf) for severely malnourished children to see the effects on recovery and sustained recovery rate.

in this stratified trial, children presenting at the health center and fulfilling the inclusion criteria will be randomly allocated into one of the study groups in a ratio of 1:1:1 for mam and 1:1 for sam. the supplementation will be done on daily basis according to the child's weight for a maximum of 12 weeks, at which point the programmatic recovery assessment is done. those who recovered before or at this point, will be subsequently followed up monthly up to 3 month for sustained recovery assessment. follow-up visits will be done at the health center every week for severe acute malnutrition (sam) children and every two weeks for moderate acute malnutrition (sam) children. at each visit, anthropometric measurements will be performed; a morbidity questionnaire will be administered before the mother/caregiver receives the ration for the following period. for the measurement of adherence, mothers will be asked to bring back empty and unused sachets/packaging of supplements from the last visit. questions will also be asked to the mother/caregiver on the difficulties encountered during consumption and the adverse events observed following the consumption of the supplements.

Eligibility criteria:
inclusion criteria: * age between 6 and 23 months * moderate wasting: whz \< -2 and ≥ -3 or muac \< 125 mm and ≥ 115mm or - severe wasting: whz \< -3 or muac \< 115 mm exclusion criteria: * bilateral pitting edema * not eating/lack of appetite * current illness medical complications requiring inpatient treatment * presence of any congenital abnormality or underlying chronic disease that may affect growth or risk of infection * known contraindication/hypersensitivity/allergy to mdcf of rusf ingredients (chickpea flour, soy flour, banana, peanut) * relapse from mam treatment or transfer from sam treatment * children recently (\<2 months) or enrolled in a nutrition program * residence outside the study area
patogenic mutation in 5 genes

Conditions: Colorectal Cancer; APC Gene Mutation; TP53 Gene Mutation; PIK3CA Gene Mutation; KRAS Mutation-Related Tumors; MLH1 Gene Mutation

Summary: this is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. apc, tp53, pik3ca, kras, and mlh1. single nucleotide variants identified were synchronized with patients' characteristics.


Eligibility criteria:
inclusion criteria: * ffpe samples fullfilling purity criterion and pass quality control exclusion criteria: * none

Keywords: next-generation sequencing colorectal cancer indonesia population co-occurring mutation
shock index to detect low plasma fibrinogen in trauma (side)

Conditions: Trauma, Multiple

Summary: shock-index is potentially an easy tool to estimate the risk of hypofibrinogenemia without the need to perform other potentially time consuming investigations.

hypofibrinogenemia is common in severe trauma and below the threshold of 2.3 g/l is associated with increased mortality. although guidelines for management of the trauma induced coagulopathy does not recommend any specific timing of fibrinogen substitution, several papers suggest that early substitution might be associated with improved outcome. laboratory measurement of plasma fibrinogen level, thromboelastometry and/or its estimation based on base excess, hemoglobin level, injury severity score or combinations require diagnostic procedures that are associated with with a certain time delay and prolongs the time to fibrinogen substitution.

Eligibility criteria:
inclusion criteria: * patient having / suspected to have severe trauma transported to participating centers by cooperating emergency medical system organizations exclusion criteria: * possible alterations of plasma fibrinogen level in the time of trauma (inflammatory disease, malignant disease, pregnancy) * administration of fibrinogen containing products (fresh frozen plasma, fibrinogen concentrate, cryoprecipitate) before sampling blood for fibrinogen level * circumstances possibly interfering with plasma fibrinogen level measurement (prior the administration of hydroxyethylstarches)
randomized controlled trial of aspirin vs placebo in the treatment of pre-psychosis

Conditions: Clinical High Risk for Psychosis

Summary: the primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (chr) syndrome for psychosis. the investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing chr symptoms. as secondary measures the investigators aim to collect laboratory studies of inflammation markers and genetic samples to determine whether certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.

patients will be randomly assigned to either active treatment (aspirin) or placebo.

Eligibility criteria:
inclusion criteria: * age 19 - 35 * must have a sips interview * chr subjects must meet at least one of 3 chr syndromes defined by sips * must demonstrate adequate decisional capacity exclusion criteria: * under age of 19 * have pre-existing gastrointestinal disease, heart disease * have kidney disease * taking non-steroidal anti-inflammatory medications * hypersensitive to nsaid (non-steroidal anti-inflammatory medications) * have coexisting unstable major medical illness * are pregnant or breastfeeding * consume more than 2 drinks of alcohol per day * have a blood clotting disorder * are taking ace inhibitors, acetazolamide, anticoagulants, anticonvulsants, beta blockers, diuretics, methotrexate, oral hypoglycemic or uricosuric agents * have a history of substance abuse in past three moths or dependence in past 6 months
digital tools for coping with chronic pain

Conditions: Chronic Pain; Depression; Anxiety; Opioid Use

Summary: chronic pain is becoming increasingly more prevalent worldwide. high rates of co-morbid psychological distress are also commonly found among individuals living with chronic pain. often requiring a multi-modal treatment approach, a growing body of literature suggests that digital behavioral health interventions and tools may serve as promising complementary options to help individuals cope with the pain.

the research objective is to evaluate the effectiveness of the mystrength product offerings, namely the chronic pain focus area, on study participants' functional well-being over time. the research questions to be answered include the following: 1. do study participants who are randomized to the mystrength intervention arm experience change in their self-reported ability to function, outlook on pain, and/or perception of prescription opioids. 2. do study participants who are randomized to the mystrength intervention arm experience change in terms of their behavioral health, such as anxiety and depression levels, during the study period. the study team hypothesizes that mystrength study participants will achieve a higher level of functioning and adopt a more positive outlook toward their pain management as compared to the waitlist control group. self-assessments will be repeated throughout the study period to capture the inflection point of change as well as the sustainability of these changes over time.

Eligibility criteria:
inclusion criteria: 1. study participants must be 18 years of age or older 2. self-report chronic pain lasting for at least the past 3 months but no more than 9 months (examples include lower back pain, arthritis, chronic headaches, neuropathic pain, knee pain) 3. must have considered, have a history of, or are currently taking a prescription opioid for chronic pain (examples oxycodone (oxycontin, percodan, percocet), hydrocodone (vicodin, lortab, lorcet), morphine (kadian, avinza, ms contin), fentanyl (duragesic), propoxyphene (darvon), hydromorphone (dilaudid) 4. fluent in english and articulate access to a laptop or mobile device to access email and the mystrength platform exclusion criteria: 1. under the age of 18 2. chronic pain due to cancer 3. chronic pain \ 9 months 4. prior exposure to the mystrength platform 5. self-reported history of hospitalization for mental illness or a substance use disorder 6. receiving government benefits related to a developmental or behavioral health disability

Keywords: digital behavioral health
tibial nerve stimulation for post-bph overactive bladder

Conditions: Persistent Overactive Bladder Symptoms Post Benign Prostatic Hyperplasia Surgery

Summary: a single-center, randomized, parallel-controlled design. approximately 90 cases of persistent overactive bladder symptoms post benign prostatic hyperplasia surgery are expected to be enrolled. the study participants will be randomly assigned to three groups, with 30 participants in each group.


Eligibility criteria:
inclusion criteria: * 1. patients with overactive bladder before benign prostatic hyperplasia 2.overactive bladder still exists 1 month after the operation of benign prostatic hyperplasia; 3.50 ≤ age ≤80 , male 4.72-hour urination diary showed an average of ≥8 urination times every 24 hours at baseline exclusion criteria: -
use of alternative medicine among outpatients in dermatology and primary care clinics

Conditions: Dermatologic Disorders

Summary: this study is to assess the practice of complementary and alternative medicine (cam) for skin related conditions among patients in the primary care and dermatology clinics.

this study aims to determine the prevalence and characteristics complementary and alternative medicine (cam) usage among primary care and dermatology clinic patients through the use of an anonymous, self-completed written survey. this survey will assess the prevalence and regularity of cam usage (with and without concurrent use of allopathic therapies), the reasons for cam usage, perceived success with cam usage, and socioeconomic status, in both dermatology and primary care patients. we will then compare these elements of cam usage between the two clinic patient populations.

Eligibility criteria:
inclusion criteria: * 18 years or older * presents for a clinic appointment with a dermatologist or primary care physician * english-speaking exclusion criteria: * less than 18 years or older * non-english speaking
progressive relaxation exercises before mobilization:effects on pain, anxiety and physiologic parameters cabg patients

Conditions: Pain; Anxiety; Physiological Parameter; Mobilization; Coronary Artery Bypass Graft Surgery (CABG); PROGRESSIVE MUSCLE RELAXATION EXERCISES

Summary: this study is planned as a randomized controlled experimental study to determine the effect of progressive relaxation exercises applied before mobilization on pain, anxiety and physiological parameters in patients undergoing coronary artery bypass graft surgery.

this study was planned as a randomized controlled experimental study to determine the effect of progressive relaxation exercises on pain, anxiety and physiological parameters before mobilization in patients undergoing coronary artery bypass graft (cabg) surgery. ethics committee and institutional approval were obtained before starting the study. patients were informed about the study and their verbal and written informed consent was obtained. the study will be conducted in a public hospital in istanbul between may 2024 and may 2025 with 68 patients (experimental group = 34, control group = 34) who met the research criteria and underwent cabg surgery. the patients in the experimental group will be given progressive relaxation exercises twice at 6-hour intervals on postoperative day 1 and day 2. patients in the control group will receive routine treatment and care. physiological parameters, pain, and anxiety levels will be evaluated twice daily on postoperative days 1 and 2 in both groups.it was also stated that a smart wristband should be worn on the arms of the patients on postoperative days 1 and 2 to monitor the frequency of mobilization in both the experimental and control groups. in addition, the frequency of analgesic use will be monitored.

Eligibility criteria:
inclusion criteria: * ability to read and write in turkish, * analgesics given ≥4h before assessment, * conscious and communicative, * elective coronary artery bypass graft surgery planned, * patients undergoing coronary artery bypass graft surgery for the first time were included in the study. exclusion criteria: * diagnosed with a psychiatric or neurological disorder, * diagnosis of a musculoskeletal condition that could affect mobilization, * patients with hearing and vision loss, * patients participating in another clinical trial during the same period, * patients who developed any complications during the postoperative period were excluded.

Keywords: coronary artery bypass graft surgery pain anxiety progressive relaxation exercise physiological parameter
informed decision users of the health system and participation in organized screening for breast cancer

Conditions: Healthy; Breast Cancer

Summary: the aim of this study is to assess the impact of a decision aid leaflet on the participation of women invited to participate in the french national breast cancer screening program.


Eligibility criteria:
inclusion criteria: * women, aged between 50 and 74 years old living in 11 french departments exclusion criteria: -

Keywords: breast cancer screening patient decision aids informed decision empowerment randomized control trial from 50 to 74 years old invited to national breast cancer screening
btx-a treatment for palmar hyperhidrosis

Conditions: Primary Focal Hyperhidrosis of the Hands

Summary: primary focal hyperhidrosis (excessive sweating) is a debilitating condition affecting approximately 3% of the population in the united states. not only that it is a major social embarrassment to affected individuals, it also has significant negative impacts on career, school, and relationship. botulinum toxin a (btx-a), a sterile neurotoxin purified from clostridium bacteria, was approved by the u.s. food \& drug administration in 2004 for the treatment of severe focal axillary hyperhidrosis that does not respond to topical antiperspirants. it is becoming a promising treatment for many patients suffering this condition. over the past decade, the medication has also been used effectively for many other forms of focal hyperhidrosis such as the hands, feet, forehead, scalp and groin. unfortunately, btx-a injection for primary focal hyperhidrosis of the palms and soles are often limited by pain and post treatment muscle weakness associated with the procedure. recent studies have demonstrated that btx-a can be delivered across the skin via electric current using a medical device, called iontophoresis (fda 510(k) clearance # k042590 or phoresor iipm700). studies with limited number of patients have demonstrated promising results with this new treatment.


Eligibility criteria:
inclusion criteria: * healthy male or non-pregnant female * age 16 and older * if \<18, parent/legal guardian willing to sign consent and accompany to visits * diagnosis of hyperhidrosis disease with a severity score (hdss) of 3 or 4 * treatment types of topical antiperspirants, iontophoresis, or systemic anticholinergics have failed to treat * able to come to 5 clinical visits during the study period exclusion criteria: * diagnosis of neuromuscular disease such as peripheral motor neuropathic diseases (e.g. amyotrophic lateral sclerosis, or motor neuropathy) * diagnosis of neuromuscular junctional disorders (e.g. myasthenia gravis or lambert-eaton syndrome) * diagnosis of dysphagia * individuals with surgical implants such as pacemakers, orthopedic hardware, etc. * individuals who are immunocompromised * systemic infectious illness or infection at the injection site(s) * known hypersensitivity to any ingredient in the formulation of the drug * organic cause of hyperhidrosis * known allergy to the ingredients in the general anesthesia * diagnosis of cardiac/pulmonary issues or disease * women who are pregnant or suspected to be pregnant

Keywords: primary focal hyperhidrosis interdermal injections iontophoresis btx-a
combined pdt and intravitreal bevacizumab vs combination of pdt, intravitreal bevacizumab and triamcinolone for neovascular amd

Conditions: Neovascular Age-Related Macular Degeneration

Summary: to compare the efficacy and safety of photodynamic therapy (pdt) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular amd.


Eligibility criteria:
inclusion criteria: * cases of active neovascular amd with visual acuity of 20/400- 20/40 exclusion criteria: * history of glaucoma or ocular hypertension * disciform scar

Keywords: photodynamic therapy, bevacizumab, triamcinolone, age-related macular degeneration, choroidal neovascular membrane